Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 139,229 182,993 316,353 638,922
Total Sell Value $12,316,080 $16,513,389 $28,948,007 $60,375,372
Total People Sold 5 5 6 8
Total Sell Transactions 11 15 24 57
End Date 2024-01-21 2023-10-20 2023-04-21 2022-04-21

   
Records found: 1303
  Page 3 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bate Kenneth Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 2,100 10,775     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-06-04 4 A $0.00 $0 D/D 15,600 76,550     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-06-04 4 A $0.00 $0 D/D 12,600 99,200     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-06-04 4 A $0.00 $0 D/D 11,400 31,590     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-06-04 4 A $0.00 $0 D/D 13,800 73,134     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-06-04 4 A $0.00 $0 D/D 50,900 229,157     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-06-04 4 S $62.52 $62,521 D/D (1,000) 178,257     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-06-04 4 A $0.00 $0 D/D 11,400 64,426     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-06-03 4 S $59.88 $59,876 D/D (1,000) 179,257     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-06-03 4 D $60.00 $213,720 D/D (3,562) 53,026     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-06-02 4 AS $57.83 $21,804 D/D (377) 20,190     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-05-31 4 D $57.96 $17,214 D/D (297) 7,993     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-31 4 D $57.96 $23,937 D/D (413) 20,567     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-05-30 5 GD $0.00 $0 D/D 180 64,246     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-05-30 4 GD $23.21 $4,178 D/D 180 56,588     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-05-29 4 D $57.50 $218,040 D/D (3,792) 59,334     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-05-22 4 AS $56.88 $56,876 I/I (1,000) 46,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-05-21 4 AS $56.19 $86,817 I/I (1,545) 47,195     -
   Lawlis V Bryan Director   –       •      –    2014-05-16 4 AS $56.87 $96,672 D/D (1,700) 9,700     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-16 4 S $56.86 $105,994 D/D (1,864) 60,950     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-16 4 AS $56.91 $57,136 D/D (1,004) 20,980     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-05-15 4 D $57.44 $283,294 D/D (4,932) 180,257     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-15 4 D $57.44 $116,948 D/D (2,036) 62,814     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-15 4 D $57.44 $62,954 D/D (1,096) 21,984     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-05-15 4 D $57.44 $71,283 D/D (1,241) 63,126     -
  1303 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 3 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us